Although direct‐acting oral anticoagulants (DOACs) have widespread first‐line use for
treatment and prevention of venous thromboembolism (VTE), uncertainty remains regarding …

Four direct‐acting oral anticoagulants (DOACs)–the thrombin inhibitor dabigatran, and the
activated factor X (FXa) inhibitors apixaban, edoxaban, and rivaroxaban–are approved in …

Background We evaluated whether rivaroxaban alone or in combination with aspirin would
be more effective than aspirin alone for secondary cardiovascular prevention. Methods In …

Background Coronary artery disease is a major cause of morbidity and mortality worldwide,
and is a consequence of acute thrombotic events involving activation of platelets and …

Background The objective of this article is to summarize the published literature concerning
the pharmacokinetics and pharmacodynamics of oral anticoagulant drugs that are currently …

BACKGROUND: A fixed-dose regimen of rivaroxaban, an oral factor Xa inhibitor, has been
shown to be as effective as standard anticoagulant therapy for the treatment of deep-vein …

Enhanced recovery after surgery (ERAS) protocols produce significant clinical and
economic benefits in a range of surgical subspecialties. There is a long tradition of applying …

Venous thrombosis is a leading cause of morbidity and mortality in industrialized countries,
especially in the elderly. Many risk factors have been identified for venous thrombosis that …

Aims The anticoagulant rivaroxaban is an oral, direct F actor X a inhibitor for the
management of thromboembolic disorders. Metabolism and excretion involve cytochrome …

Background A fixed-dose regimen of rivaroxaban, an oral factor Xa inhibitor, has been
shown to be as effective as standard anticoagulant therapy for the treatment of deep-vein …